Discovery of triazines as potent, selective and orally active PDE4 inhibitors
Authors:
- Rainer GewaldRGRainer Gewald
- Christian GrunwaldCGChristian Grunwald
- Ute EgerlandUEUte Egerland
- 1 August 2013
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 23 (15) , 4308-4314
Abstract
No abstract availableKeywords
Funding Information
- European Fund for Regional Development (EFRE)
- Free State of Saxony (SAB 8093)
This publication has 27 references indexed in Scilit:
- Discovery of oxazole-based PDE4 inhibitors with picomolar potencyBioorganic & Medicinal Chemistry Letters, 2012
- Synthesis and biological activity of pyrido[3′,2′:4,5]furo[3,2-d]pyrimidine derivatives as novel and potent phosphodiesterase type 4 inhibitorsEuropean Journal of Medicinal Chemistry, 2011
- Synthesis and Biological Activity of Pyrido[3′,2′:4,5]thieno[3,2-d]pyrimidines as Phosphodiesterase Type 4 InhibitorsJournal of Medicinal Chemistry, 2010
- Pyrazolopyridines as potent PDE4B inhibitors: 5-Heterocycle SARBioorganic & Medicinal Chemistry Letters, 2010
- PDE4 inhibitors: a review of current developments (2005 – 2009)Expert Opinion on Therapeutic Patents, 2009
- Discovery of selective PDE4B inhibitorsBioorganic & Medicinal Chemistry Letters, 2009
- Cyclic nucleotide phosphodiesterase (PDE) superfamily: A new target for the development of specific therapeutic agentsPharmacology & Therapeutics, 2006
- Enantiomer Discrimination Illustrated by the High Resolution Crystal Structures of Type 4 PhosphodiesteraseJournal of Medicinal Chemistry, 2006
- A view into the catalytic pocket of cyclic nucleotide phosphodiesterasesNature Structural & Molecular Biology, 2004
- Synthesis and Antitumor Activity of Pt(II) Complexes of Benzyl‐1,2‐diaminoethane LigandsEuropean Journal of Inorganic Chemistry, 1990